McGill, Moderna launch two new projects in lipid nanoparticle research

McGill University and Modern TX, Inc recently announced that they are collaborating on two lipid nanoparticle (LNP) research projects. LNPs are vital components in mRNA medicines, including vaccines. The first project will run for three years and will investigate how to enhance the cell-specific delivery of cargo, like mRNA. The second project will run for an initial one-year period and will characterize LNPs so that their specific size and payload distribution is better understood. “With Moderna’s support, these two highly specialized research projects have the potential to accelerate the application of LNPs in the development and delivery of mRNA therapies for a range of diseases,” said McGill Vice-Principal, Research and Innovation Martha Crago.